Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,252.20
Bid: 1,253.20
Ask: 1,253.60
Change: 0.00 (0.00%)
Spread: 0.40 (0.03%)
Open: 1,248.00
High: 1,255.60
Low: 1,221.60
Yest. Close: 1,243.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

2nd UPDATE: AstraZeneca Profit Drops As It Bolsters Drug Portfolio

5 Feb 15 07:41

AstraZeneca Profit Drops As It Moves To Further Bolster Drug Pipeline

5 Feb 15 07:34

AstraZeneca Profit Drops As It Moves To Further Bolster Drug Pipeline

5 Feb 15 07:15

MARKET COMMENT: Retreat In World Oil Price Flattens London Equities

4 Feb 15 17:42

UPDATE 2-Genmab data seen pointing to blockbuster drug

(Adds GlaxoSmithKline selling 7.9 pct stake in Genmab) By Teis Jensen COPENHAGEN, Feb 4 (Reuters) - Positive results from a trial by biotech company Genmab of its bone marrow cancer treatment could lead to the launch of a blockbuster drug earning $3.5 billion a year, analysts said on

4 Feb 15 17:21

London close: Stocks trim losses on Greek hopes, Chinese stimulus

A late rally helped the FTSE 100 to erase most of its losses on Wednesday as optimism surrounding Greece and stimulus measures in China lifted sentiment, though stocks still finished in the red after hitting a five-month high the previous day. London's Footsie ended the session down 0.2% at 6,860.02

4 Feb 15 17:09

REFILE-GSK sells stake in Denmark's Genmab

(Refiles to fix formatting error) LONDON, Feb 4 (Reuters) - GlaxoSmithKline has put its 7.9 percent stake in Danish biotech company Genmab up for sale to institutional investors, the British drugs giant said on Wednesday. "Since the announcement of the sale of GSK's marketed Oncology

4 Feb 15 16:42

GSK sells stake in Denmark's Genmab

LONDON, Feb 4 (Reuters) - GlaxoSmithKline has put its 7.9 percent stake in Danish biotech company Genmab up for sale to institutional investors, the British drugs giant said on Wednesday. "Since the announcement of the sale of GSK's marketed Oncology portfolio to Novartis, GSK has consider

4 Feb 15 16:27

GlaxoSmithKline To Sell Its 7.9% Stake In Denmark's Genmab Via Placing

4 Feb 15 16:24

UPDATE 2-GlaxoSmithKline sees better signs for lung drugs after tough 2014

* Q4 sales 6.19 billion stg vs consensus 6.20 billion stg * Q4 core EPS 27.3 pence versus consensus 25.9 pence * Sees signs of regaining respiratory market share * Novartis deal on track to close in first half of 2015 (Adds further CEO comment, analyst, updates shares) B

4 Feb 15 15:02

Sector movers: GSK leads defensive pharma stocks higher

A massive cash return by Glaxosmithkline gave the wider sector a lift on Wednesday, with defensive healthcare and pharmaceutical stocks also benefiting from a reduction in risk appetite as UK markets pulled back from a five-month high. Sales, profits and earnings slumped during the fourth quarter of

4 Feb 15 14:35

UPDATE 1-GSK gives roadmap for potential 2016 listing of HIV drugs business

* Citi, Goldman and Morgan Stanley hired on ViiV -sources * GSK CEO sees board deciding mid-2015 on IPO plans * Two new HIV drugs performing better than expected (Recasts with GSK CEO comments) By Ben Hirschler LONDON, Feb 4 (Reuters) - GlaxoSmithKline set out a roadmap

4 Feb 15 14:14

FTSE 100 movers: Hargreaves Lansdown falls short of expectations, Sky higher on strong interim figures

Half-yearly results from fund manager and savings outfit Hargreaves Lansdown showed record assets under administration and growing client numbers, though shares fell sharply after revenues and profits came in shy of City expectations. Analysts at Shore Capital said: "The figures show a slight improv

4 Feb 15 13:51

2nd UPDATE: Glaxo Pretax Profit Down, Still Mulling Potential ViiV IPO

4 Feb 15 13:48

BUZZ-GlaxoSmithKline Plc: Higher-than-expected Q4 profit

** British drugmaker's U.S.-listed shares up 2.5 pct at $45.35 premarket ** Company reports better-than-expected Q4 earnings, helped by cost cuts ** GSK reports lower-than-expected Q4 revenue, hurt by weak sales of lung drug Advair ** Up to Tuesday's close, U.S.-listed stock had

4 Feb 15 13:37

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.